SOURCE: ONE Bio, Corp.

August 24, 2010 08:00 ET

ONE Bio Reports Second Quarter 2010 Results

Q2 Revenue, Operating Income and Net Income increase 484%, 323% and 281% respectively

MIAMI, FL--(Marketwire - August 24, 2010) -  ONE Bio, Corp. ("ONE" or the "Company") (OTCBB: ONBI), an innovative company utilizing green process manufacturing to produce raw chemicals and herbal extracts, natural and health supplements and organic products, announced results for the second quarter and YTD for 2010.

Second Quarter of Year 2010 Results:
Second quarter 2010 revenue was up 484% to $12,679,797 compared to $2,169,748 for the same period a year ago. Operating Income was up 323% to $3,563,519 compared to $841,466 for the same period last year. Net Income was up 281% to $2,349,393 compared to $615,857 for the same quarter last year. Earnings per share for the second quarter of 2010 reached $0.08 compared to $0.03 for the same period in 2009. Gross margin was 38.9% and income from operations margin remained strong at 28.1% during the quarter.

YTD (First 6 Months) 2010 Results:
YTD 2010 revenue ended June 30, 2010 now reaches $23,842,304 compared to $4,467,369 for the first two quarters last year, an increase of 434%. YTD 2010 operating income now reaches $6,456,362 compared to $1,981,689 (up 226%) form the same period last year. YTD 2010 net income now reaches $3,986,468 compared to $1,458,582 (up 173%) form the same period last year. Earnings per share for the first 6 months of 2010 now reach $0.13 compared to $0.06 for the same period in 2009.

  Three Months ended June 30,   Six Months ended June 30,
  2010   2009   2010   2009
Revenues $ 12,679,797   $ 2,169,748   $ 23,842,304   $ 4,467,369
Cost of sales   7,748,113     988,587     14,802,909     1,841,273
Gross profits   4,931,684     1,181,161     9,039,395     2,626,096
                       
Operating expenses                      
  General and administrative expenses   1,142,459     267,760     2,259,302     494,811
  Research and development expenses   53,220     36,573     113,608     73,039
  Selling and marketing expenses   172,486     35,362     210,123     76,557
    1,368,165     339,695     2,583,033     644,407
                       
Income from operations   3,563,519     841,466     6,456,362     1,981,689
Interest and financing expense   (175,181)     1,423     (374,290)     1,672
Interest income   8,781     (8,318)     12,619     (8,406)
Other income   (196,595)     -     (360,723)     -
                       
Income before income taxes   3,200,524     834,571     5,733,968     1,974,955
Provision for income taxes   (801,685)     (218,714)     (1,504,200)     (516,373)
                       
Net income bef Non-controlling interest   2,398,839     615,857     4,229,768     1,458,582
Non-controlling interest   (49,446)     -     (243,300)     -
Net Income $ 2,349,393   $ 615,857   $ 3,986,468   $ 1,458,582
                       
Earnings per share                      
- Basic   $0.08     $0.03     $0.13     $0.06
- Diluted   $0.07     $0.03     $0.12     $0.06
                       
Weighted avg number of shares:                      
- Basic   29,689,528     23,563,061     29,689,528     23,563,061
- Diluted   34,932,232     23,563,061     34,327,106     23,563,061

"We are very pleased with our second quarter results. These results reflect strong organic growth and the contribution of our completed acquisitions. Asia's robust economic growth continues to fuel demand for our products," stated Marius Silvasan, ONE's CEO. "We have launched several new products during the quarter which have helped lift our sales. We have also during the quarter expanded distribution in commercial supermarkets and pharmacy store chains in China. We now distribute, amongst others, to Wal-Mart, Yonghui and Xinhua including renowned pharmacy chains such as Jonghui and Huihao. We anticipate seeing continued growth for the remainder of the year," added Silvasan.

About ONE Bio, Corp.
ONE Bio, Corp. ("ONE") (OTCBB: ONBI) (www.onehcorp.com) headquartered in Miami, FL, is an innovative company utilizing green process manufacturing to produce raw chemicals and herbal extracts, natural supplements and organic products. ONE is focused on capitalizing on the rapidly growing markets of the Asia Pacific region. Key products include widely recognized Solanesol, CoQ10, Resveratrol and 5-HTP, organic fertilizers, and organic bamboo health food and beverages. ONE's growth plan targets an aggressive acquisition driven strategy supported by strong organic growth. Through ONE, small private companies gain access to capital, experienced management and strategic insight. ONE builds strong synergies amongst all subsidiaries to enhance shareholder value. ONE is working with each subsidiary to promote organic and acquisition driven growth.

This press release includes statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). ONE Bio, Corp. claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms "may," "believes," "projects," "expects," or "anticipates," and do not reflect historical facts. Specific forward-looking statements contained in this press release include, but are not limited to: our successful integration of diversified growth companies, impact of the company's expansion plan, and new business development success, future financial results, development and acquisition of new product lines and services, the impact of competitive products or pricing from technological changes, the effect of economic conditions and other uncertainties. The forward-looking statements contained herein involve risks and uncertainties that could cause actual results to differ materially from the expectations contained in any such forward-looking statements. These risks include, but are not limited to: failure to manage operating expenses or integrate new companies and/or technologies, each of which could have a material impact on our business, our financial results, and the company's stock price. These risks and other factors are detailed in the Company's regular filings with the U.S. Securities and Exchange Commission. Most of these factors are difficult to predict accurately and are generally beyond the Company's control. Forward-looking statements speak only as to the date they are made and ONE Bio, Corp. does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

Contact Information